Table 2 Baseline characteristics after inverse probability of treatment weighting
Characteristics | After IPTW | ||||
|---|---|---|---|---|---|
Warfarin (N = 69,168) | Apixaban (N = 67,947) | Dabigatran (N = 68,716) | Rivaroxaban (N = 68,882) | Maximum pairwise ASD | |
Age | 70.4 ± 11.3 | 70.7 ± 11.1 | 70.5 ± 11.2 | 70.6 ± 11.1 | 0.011 |
< 65 years | 26.2% | 25.2% | 25.5% | 25.6% | 0.012 |
65–74 years | 33.1% | 33.6% | 33.8% | 33.4% | 0.008 |
≥ 75 years | 40.7% | 41.2% | 40.7% | 41.0% | 0.006 |
Women | 41.4% | 41.7% | 41.2% | 41.4% | 0.011 |
AF duration, months | 30.9 ± 44.9 | 31.3 ± 45.1 | 31.3 ± 45.1 | 31.4 ± 45.2 | 0.006 |
High tertile of income | 44.1% | 44.9% | 44.4% | 44.7% | 0.008 |
Risk scores | |||||
CHA2DS2-VASc | 4.3 ± 2.1 | 4.3 ± 2.0 | 4.3 ± 2.0 | 4.3 ± 2.0 | 0.006 |
HAS-BLED | 5.3 ± 3.2 | 5.3 ± 3.1 | 5.3 ± 3.1 | 5.3 ± 3.2 | 0.004 |
Charlson comorbidity index | 5.5 ± 6.5 | 5.4 ± 6.4 | 5.4 ± 6.5 | 5.4 ± 6.5 | 0.005 |
Medical conditions | |||||
Congestive heart failure | 57.9% | 57.9% | 57.9% | 58.2% | 0.004 |
Hypertension | 81.5% | 81.3% | 81.4% | 81.6% | 0.004 |
Diabetes mellitus | 31.1% | 30.9% | 30.7% | 30.7% | 0.005 |
Dyslipidemia | 86.7% | 87.2% | 87.1% | 87.1% | 0.006 |
Ischemic stroke | 33.3% | 33.5% | 33.5% | 33.1% | 0.005 |
Transient ischemic attack | 10.5% | 10.7% | 10.9% | 10.7% | 0.005 |
Intracranial hemorrhage | 1.6% | 1.7% | 1.7% | 1.7% | 0.004 |
Previous MI | 12.1% | 11.8% | 11.8% | 11.8% | 0.005 |
Peripheral artery disease | 19.0% | 18.8% | 19.1% | 18.9% | 0.005 |
Chronic kidney disease | 8.6% | 8.6% | 8.3% | 8.4% | 0.008 |
Proteinuria | 9.0% | 9.0% | 8.8% | 8.6% | 0.008 |
Osteoporosis | 37.5% | 37.9% | 37.7% | 37.5% | 0.005 |
COPD | 22.5% | 22.2% | 22.2% | 22.4% | 0.004 |
Chronic liver disease | 46.7% | 46.9% | 46.6% | 46.7% | 0.002 |
Malignant neoplasm | 28.7% | 29.2% | 28.6% | 29.0% | 0.008 |
Hyperthyroidism | 13.1% | 13.1% | 12.9% | 13.1% | 0.003 |
Hypothyroidism | 13.8% | 14.0% | 13.9% | 14.0% | 0.003 |
History of fall | 0.5% | 0.5% | 0.5% | 0.5% | 0.004 |
History of any fracture | 19.6% | 19.6% | 20.0% | 19.9% | 0.006 |
History of major fracture | 9.1% | 8.9% | 8.9% | 9.1% | 0.006 |
Rheumatoid arthritis | 2.2% | 2.1% | 2.2% | 2.2% | 0.002 |
Recent medication use | |||||
Antiplatelet agents | 16.2% | 15.5% | 16.1% | 15.8% | 0.011 |
Statin | 44.3% | 44.9% | 44.9% | 44.8% | 0.006 |
β-blocker | 52.0% | 52.8% | 52.2% | 52.4% | 0.008 |
ACEi/ARB | 58.3% | 59.0% | 58.4% | 58.8% | 0.008 |
DHP CCB | 48.7% | 49.4% | 49.0% | 48.9% | 0.008 |
Non-DHP CCB | 11.6% | 11.9% | 11.9% | 11.8% | 0.005 |
Loop/thiazide diuretics | 56.8% | 56.5% | 56.4% | 56.7% | 0.006 |
K+ sparing diuretics | 14.3% | 14.3% | 14.2% | 14.3% | 0.001 |
Digoxin | 16.8% | 16.5% | 16.9% | 16.7% | 0.006 |
AAD class Ic | 6.7% | 7.0% | 7.1% | 6.9% | 0.009 |
AAD class III | 5.3% | 5.5% | 5.4% | 5.4% | 0.005 |
Alpha blocker | 10.1% | 9.8% | 9.8% | 9.8% | 0.005 |
Systemic glucocorticoid | 23.5% | 24.1% | 23.5% | 23.8% | 0.009 |
Antidepressant | 16.7% | 16.9% | 17.0% | 17.1% | 0.005 |
Bisphosphonate | 15.6% | 15.7% | 15.7% | 15.8% | 0.002 |
Proton-pump inhibitor | 28.2% | 28.8% | 28.8% | 28.6% | 0.007 |